At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
selumetinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of AZD6244 in Biliary Cancers
In Brief
A Phase 2 clinical trial evaluating selumetinib and laboratory biomarker analysis for Liver and Intrahepatic Biliary Tract Cancer and 2 related conditions. Completed, enrolled 29 participants across 7 sites.
Detailed Summary
This phase II trial is studying how well selumetinib works in treating patients with biliary cancer that cannot be removed by surgery. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver and Intrahepatic Biliary Tract Cancer, Recurrent Extrahepatic Bile Duct Cancer, Unresectable Extrahepatic Bile Duct Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
First PostedNov 2007
Primary CompletionJan 2013
TodayJul 2026
First PostedNov 5, 2007
Enrollment StartNov 1, 2007
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 18.7 years ago
Interventions
selumetinibdrug
Given orally
laboratory biomarker analysisother
Correlative studies